MacNeil Capital Management

Founder and President Robert MacNeil directs all investment decisions. He established the firm in 1979 and remains the sole named principal in public filings and corporate records.

The firm concentrates on deeply discounted micro-cap equities, pharmaceutical royalty trusts, and real estate acquired through tax-lien foreclosures and bankruptcy auctions. Public records identify timber holdings in North Carolina and a Delaware-incorporated pharma royalty entity, reflecting an approach that rarely overlaps with institutional benchmarks.

No. It functions as a permanent-capital holding company rather than a fund with quarterly redemptions. MacNeil does not appear to file 13F ownership reports or maintain a standard investor relations function, suggesting a proprietary or closely held capital base rather than a pooled third-party fund structure.

Sourcing relies on monitoring bankruptcy court dockets, SEC deregistration filings, corporate trust liquidations, and county tax-lien sale notices — channels that fall outside the broker-dealer research most funds depend on. Positions often involve securities that have been orphaned by forced index deletions or institutional mandate screens.

MacNeil applies a liquidation-value discipline to illiquid claim types — pharmaceutical royalty rights and tax-repossessed land — rather than standard operating companies. The permanent-capital structure removes the pressure to liquidate positions before post-reorganization catalysts materialize, a constraint that historically limits distressed-value strategies within drawdown fund formats.